Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
16.20
-0.76 (-4.48%)
Mar 6, 2026, 3:59 PM EST
60.71%
Market Cap 334.16M
Revenue (ttm) n/a
Net Income (ttm) -30.04M
Shares Out 20.63M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,957
Average Volume 29,587
Open 17.15
Previous Close 16.96
Day's Range 16.20 - 17.15
52-Week Range 6.24 - 18.98
Beta 0.71
RSI 55.58
Earnings Date Mar 27, 2026

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 17
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.